SCHEMBL30195938

SCHEMBL30195938

O=C(Nc1ccc(C(F)(F)F)cc1)Nc1c[nH]c2ccc(-c3ccc(F)c(F)c3)cc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 7/20 0.65
▸ EPHX2 P34913 1/20 0.48
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ NTRK1 P04629 1/20 0.46
▸ RET P07949 1/20 0.46
▸ PDGFRB P09619 1/20 0.46
▸ LTK P29376 1/20 0.46
▸ CDK8 P49336 1/20 0.46
▸ NTRK3 Q16288 1/20 0.46
▸ MAPK14 Q16539 1/20 0.46
▸ NTRK2 Q16620 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ GOT1 P17174 1/20 0.45
▸ KDR P35968 3/20 0.45
▸ BRAF P15056 1/20 0.45
▸ KIT P10721 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23207917 1.00 STING1 (0.65) STING1EPHX2CA12CA1CA2
SCHEMBL23207649 0.89 STING1 (0.65) STING1EPHX2GOT1GRIK1
SCHEMBL23208193 0.89 STING1 (0.65) STING1EPHX2GOT1GRIK1MTOR
SCHEMBL23207771 0.89 STING1 (0.62) STING1EPHX2FLT3GOT1KDR
SCHEMBL30195930 0.89 STING1 (0.62) STING1EPHX2FLT3GOT1KDR
SCHEMBL23208059 0.89 STING1 (0.62) STING1EPHX2CA12CA1CA2
SCHEMBL23208192 0.88 STING1 (0.67) STING1EPHX2FLT3GOT1KDR
SCHEMBL23167861 0.88 STING1 (0.73) STING1EPHX2FLT3NTRK1NTRK2
SCHEMBL23207945 0.88 STING1 (0.66) STING1EPHX2FLT3NTRK1NTRK2
SCHEMBL23208067 0.87 STING1 (0.65) STING1EPHX2GOT1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885EPHX2 730/4885CA12 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback